Priority 4 from the Hidradenitis Suppurativa PSP
| UNCERTAINTY: How effective are biologics (etanercept, adalimumab, infliximab, ustekinumab) in treating Hidradenitis Suppurativa? (JLA PSP Priority 4) | |
|---|---|
| Overall ranking | 4 |
| JLA question ID | 0017/4 |
| Explanatory note | Not available for this PSP |
| Evidence |
Ongoing studies: A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) AbbVie. ~NCT01635764~~A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (HiTS)~NCT01704534 Protocol for Systematic Review: Ingram JR, Desai N, Kai AC, Chua SL, Woo P-N, Kerdel F, Burton T, Ormerod AD, Garner SE, Hood K, Piguet V. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010081. DOI: 10.1002/14651858.CD010081 |
| Health Research Classification System category | Skin |
| Extra information provided by this PSP | |
|---|---|
| Comparison | Vaccines and biologicals |
| Submitted by | 20 patients, 96 clinicians |
| Outcomes to be measured | Management and or change of symptoms (pain, Hidradenitis Severity Score, time to remission and duration of remission, physician and patient assessment of change ); adverse effects* (morbidity, hospital admission), or complications (adverse effects leading to treatment discontinuation ,increased duration of treatment); acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life*; and health related costs. *Signifies Primary outcomes |
| PSP information | |
|---|---|
| PSP unique ID | 0017 |
| PSP name | Hidradenitis Suppurativa |
| Total number of uncertainties identified by this PSP. | 55 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 6 December 2013 |